Triazolam impairs inhibitory control of behavior in humans

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


This study tested the effects of the sedative-hypnotic drug triazolam (Halcion) on the ability to inhibit behavior in humans. Thirty adults practiced a stop-signal task that measured their ability to inhibit and activate behavioral responses on a choice reaction time task. Equal numbers of participants (i.e., n = 10) then received either 0.25 mg, 0.125 mg, or 0 mg (placebo) of triazolam under double-blind conditions and performed the task intermittently over a 3-hr period. In accord with the hypothesis, triazolam reduced response inhibitions and increased the time required to inhibit a response. The drug also slowed the activation of responses. The findings contribute to the understanding of the basic behavioral mechanisms by which sedative-hypnotic drugs can produce states of behavioral disinhibition in some individuals.

Original languageEnglish
Pages (from-to)363-371
Number of pages9
JournalExperimental and Clinical Psychopharmacology
Issue number4
StatePublished - 2001

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Triazolam impairs inhibitory control of behavior in humans'. Together they form a unique fingerprint.

Cite this